
Kardigan develops personalized cardiovascular medicines intended to move patients beyond symptom management toward functional cures. The company uses a proprietary Cardiac Intelligence R&D platform and AI-based analytics to identify biomarkers for safety, efficacy, and patient responder selection prior to human trials. Kardigan is a clinical-stage biopharmaceutical company that integrates biomarker-driven patient selection and data-driven trial design into its development programs. The company is building a portfolio of therapies that target underlying cardiovascular disease pathophysiology to address unmet needs in heart health.

Kardigan develops personalized cardiovascular medicines intended to move patients beyond symptom management toward functional cures. The company uses a proprietary Cardiac Intelligence R&D platform and AI-based analytics to identify biomarkers for safety, efficacy, and patient responder selection prior to human trials. Kardigan is a clinical-stage biopharmaceutical company that integrates biomarker-driven patient selection and data-driven trial design into its development programs. The company is building a portfolio of therapies that target underlying cardiovascular disease pathophysiology to address unmet needs in heart health.
About Us Kardigan is a heart health company working to make cardiovascular disease preventable, curable and no longer the leading cause of death in the world.
It is Kardigan’s mission to develop multiple targeted treatments in parallel that bring people with cardiovascular diseases to the cures they deserve.
Led by Tassos Giannakakos, Jay Edelberg, M.D. and Bob McDowell, Ph.D., Kardigan’s co-founders have reunited after leading MyoKardia to discover and develop mavacamten, the first cardiac myosin inhibitor, resulting in an acquisition by Bristol Myers Squibb in 2020.
We have a cutting-edge discovery and translational research platform, a pipeline of late-stage candidates, and an industry-leading team that is driven to improve the lives of patients.
At Kardigan, we are motivated by our values which guide how we work, interact, and achieve our goals. , we are deeply committed to improving the lives of patients and prioritizing their needs above all else. We believe in —leading with truth to bring out the best in others by creating an environment where every person knows they will be fully accepted. With an , we encourage the highest levels of curiosity and are open to changing our minds. We are committed to with urgency, excellence, and intention, and support each other no matter what role we play or where we sit. Lastly, we strive to because patients are counting on us. We are not afraid to take risks to unlock innovation and advance scientific discoveries.
These values are the foundation of our work, empowering us to make a real difference, every day.
Prolaio is looking to bring on a Divisional Controller & Head of Finance who will lead the finance function at Prolaio, serving as a strategic partner to R&D and operational teams while ensuring strong financial planning, analysis, and accounting oversight. Employed by Kardigan and embedded within Prolaio, this role is responsible for driving financial strategy, supporting business decision-making, and ensuring scalable, compliant financial operations in a fast-growing health technology environment. Reporting to Kardigan’s VP of Finance and Accounting, the Director will play a key role in aligning Prolaio’s financial goals with Kardigan’s broader financial objectives.
This role will report directly to Kardigan’s VP, Finance and Accounting, and work closely with the Prolaio Leadership Team.
The Specifics
Experience And Education
Exact Compensation may vary based on skills, experience and location.
Pay range
$181,000 - $205,000 USD